3rd ESTRO Forum 2015 1.31), p=0.91; 74Gy vs 57Gy: HR 1.02 (0.74-1.30), p=0.86). Analysis of change from pre-RT showed no evidence of a difference between treatment groups (figure 1).
Purpose/Objective: To evaluate the feasibility and preliminary toxicity results of a prospective randomized multicenter phase II trial of short vs. protracted urethra-sparing stereotactic body radiotherapy (SBRT) for localized prostate cancer. Materials and Methods: A total of 93 cT1-3a N0 M0 prostate cancer patients with a lymph-node involvement risk ≤ 20% were randomized between September 2012 and October 2014 to be treated with an SBRT protocol of 36.25 Gy in 5 fractions of 7.25 Gy either over 9 days (Arm A, n=45) or over 28 days once-a-week, the same week-day (Arm B, n=48) . The dose to the prostatic urethra with a surrounding margin of 3 mm (urethral planning risk volume, uPRV) was reduced to 32.5 Gy in 5 fractions (NTD 2Gy of 74 and 62 Gy for an α/β ratio of 1.5 and 3 Gy, respectively). Tolerance to the treatment was scored using the Common Toxicity Criteria for Adverse Events ver. 4.0 grading scale, the International Prostate Symptom Score (IPSS) and the EORTC QLQ-PR25 quality of life (QoL) questionnaire. Thirty-seven patients in Arm A and 38 patients in Arm B have completed treatment. Their follow-up (FU) extended up to 18 months and in Arm A 70% has reached their six month evaluation, while 60% of the patients in Arm B did. Results: SBRT was delivered to all patients as planned with no treatment interruptions. Overall genitourinary and gastrointestinal toxicities were below the stopping rule established for the study, with grade 2 toxicity reported in 6 patients for each arm mostly after the 5 th fraction. Only one patient experienced late grade 3 rectal toxicity, with the need of blood transfusion and endoscopic coagulation for the bleeding, between the 7 th and 12 th month FU. Mean IPSS scores increased significantly between baseline and the 5 th fraction (p<0.01) in both treatment arms, returning to baseline at week 12. Mean IPSS values at baseline, after the 5 th fraction and after 12 weeks were 7.5, 14 and 7.5 for Arm A and 8.1, 12.7 and 8.9 for Arm B, respectively. No significant differences were observed in EORTC QLQ-PR25 QoL endpoints between baseline and week 12 in either study arm. Conclusions: Preliminary results demonstrated the feasibility and the acceptable toxicity rates of this short vs. protracted urethra-sparing prostate SBRT phase II trial. Three months after randomization complete recovery from side effects and return to baseline IPSS scores was observed in both treatment schedules.
However, some studies showed that adjuvant HT may be associated with worse radio-induced toxicity although this topic remains controversial. Therefore, the purpose of this study was to evaluate the impact of the HT (in terms of drug type and duration) on acute and late toxicity in patients undergoing RT for PCa. Materials and Methods: We collected data from 8 clinical trials on RT of PCa. Acute toxicity was assessed according to the RTOG scale and late toxicity according to RTOG-EORTC scale. The results in terms of acute toxicity were compared with the chi-square test. Late toxicity actuarial cumulative incidence was calculated by Kaplan-Meier method and the comparison between survival curves was performed using logrank test (univariate analysis) and Cox's Proportional Hazard Method (multivariate analysis using as covariates: RT dose, fractionation and prophylactic lymph node irradiation). Results: Overall 346 patients were included in this analysis (median age: 72 years, range: 50-82; median RT dose: 70 Gy, range: 65-80; LH-RH analogue: 51.4%, high-dose antiandrogen [bicalutamide 150 mg/die]: 48.6%; HT for 6 months: 50.3%, HT for 24 months: 49.7%). The results of the statistical analysis are shown in the table.
The higher incidence of GI late toxicity in patients receiving adjuvant hormone therapy with LH-RH analogue was confirmed by multivariate analysis (p: 0.038).
Conclusions:
In an evaluation of radiation-induced toxicity in patients undergoing RT plus adjuvant HT, a higher incidence of late GI toxicity was recorded in patients treated with LH-RH analogues compared with patients treated with antiandrogen. This result warrants further studies to optimize adjuvant therapies in patients with PCa. (MRI) . Every patient received first HDRB as boost and 4 gold fiducials were implanted. Finally, all patients received EBRT by intensity modulated radiotherapy technique with imaging guided by CBCT. The patients received HDRB as a single 15 Gy implant, followed by EBRT to 46 Gy in 23 fractions. Thirty seven percent of the high-risk patients presented seminal vesicles invasion receiving a single 9.5 Gy implant, followed by ERBT to 60 Gy in 30 fractions. A total of 117 patients (52%) received a dose of 46 Gy to the true pelvis. In all brachytherapy plans, the constraints indicated in the GEC/ESTRO recommendations have been respected (Rectum D2cc £75Gy EQD2; Urethra D10£ 120Gy EQD2). Most patients (120; 54%) were prescribed complete androgen deprivation therapy (ADT), 66 (29%) received incomplete ADT and 28 (13%) did not receive ADT. GI and GU toxicity was evaluated utilizing the RTOG criteria. Median follow-up was 26 months. Results: No treatment failure has been observed to the last follow-up. The incidences of any acute ≥ Grade 2 GI or GU toxicities were 0% and 9% respectively. Dysuria and urgency was prevalent symptoms in acute GU toxicity. Late genitourinary toxicity included 2 patients (0.9%) with urine obstruction requiring intermittent/permanent catheter. One case of grade 2 gastrointestinal late toxicity presented actinic rectitis event. Conclusions: The use of a single 15Gy fraction HDRB as pretreatment EBRT boost provides early-term and good outcomes in treatment-related toxicity. These data can help physicians to assess this scheme of radiotherapy as an acceptable option in the prostate carcinoma treatment. Purpose/Objective: The use of hypofractionation allows to reduce the duration of radiotherapy (RT) and is theorically associated with an improved probability of cure in patients with prostate cancer (CAP). However, hypofractionated RT could be associated to an higher incidence of late side effects. Several studies are in progress to valuate efficacy of this irradiation modality but there are no definitive indications about tolerability and efficacy of this
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